Why Is PULSE BIOSCIENCES IN (PLSE) Stock Up Today?

Why PLSE stock is up today

Pulse Biosciences stock rose 7.22% to $35.16 in morning trading after Oppenheimer raised its price target for the company. The move followed the release of new data related to the company's atrial fibrillation (AF) program. The stock opened lower but quickly reversed course, reaching a session high of $35.49 before settling near $35.16.

What Happened

Oppenheimer increased its price target for Pulse Biosciences, citing positive developments from the company's AF data. This analyst action came after Pulse Biosciences reported first-quarter earnings that beat estimates, with a loss of $0.27 per share and revenue of $401,000. The company's CEO and a director also participated in a recent $13.3 million share purchase through an ATM program. These insider transactions occurred on May 11 and were reported in SEC filings. Pulse Biosciences is currently unprofitable, with an earnings per share of -1.10 in the trailing twelve months.

What The Data Shows

The stock opened at $32.62, which was a 0.5% gap down from the prior close of $32.79. It reached a high of $35.49 at 11:35 AM ET and a low of $32.28 at the market open. The session volume was 0.1 million shares, which is 0.4 times the 3-month daily average. The stock is currently trading within its 52-week range of $12.56 to $33.87, and its market capitalization is $2.1 billion. The stock has a beta of 1.65, indicating higher volatility than the broader market.

What To Watch

Investors will be looking ahead to Pulse Biosciences' earnings report, which is scheduled for May 4, 2026. The company's ability to maintain momentum following the recent analyst upgrade and insider buying activity will be key to watch. Coverage breadth is also a factor, as only one story has been published in the last 36 hours.